Evidence for Neurotoxicity from Quinoline Antimalaria Drugs: Four Personal Accounts  

作　　者：Ashley M. Croft Anthony R. Mawson 

机构地区：[1]School of Pharmacy and Biomedical Science, University of Portsmouth, Portsmouth, UK [2]School of Public Health (Initiative), Jackson State University, Jackson, MS, USA

出　　处：《Open Journal of Animal Sciences》2017年第1期45-55,共11页动物科学期刊（英文）

摘　　要：Background: The adverse effects of mefloquine and other quinoline antimalaria drugs can be severe and long-lasting. We believe that the trigger for these effects may be drug-induced hepatocellular damage that causes, firstly, a spillage of retinoids into the circulation (and hence a direct toxic effect on the brain and other target organs), and secondly, disruption of the liver-thyroid axis (and hence a pattern of specific bipolar symptoms such as is often seen in thyroid disease). Methods: We sought recently-published lay accounts of adverse effects in users of quinoline antimalaria drugs, to test these lay descriptions against our hypothesis on the likely pathogenesis of these effects. Results: We found six lay accounts that described four different experiences of adverse effects arising from the prophylactic use of quinoline antimalaria drugs. All four travellers were healthy, at the start of travel. Two of the travellers experienced severe psychoses, and one had a mild psychosis. The fourth traveller, a serving US soldier, killed 16 unarmed Afghan civilians. Analysis of these accounts shows that, based on our hypothesis, all four travellers had at least one risk factor (most commonly, concurrent alcohol use), for developing a severe reaction to their quinoline antimalaria drug. Our hypothesis therefore predicted a severe adverse drug reaction in each of these four travellers. We also identified a hitherto unrecognized risk factor for developing a severe reaction to quinoline antimalaria drugs—namely, the concurrent use of anabolic steroids. Conclusions: Lay accounts of drug adverse effects can help initiate or further develop medical hypotheses of their pathogenesis. We advise that the quinoline class of antimalaria drugs should be prescribed cautiously, and that mefloquine should not now be prescribed for malaria prophylaxis, under any circumstances whatsoever. Where persistent adverse effects have resulted from the historical use of quinoline antimalaria drugs, we propose a five-point management strategy Background: The adverse effects of mefloquine and other quinoline antimalaria drugs can be severe and long-lasting. We believe that the trigger for these effects may be drug-induced hepatocellular damage that causes, firstly, a spillage of retinoids into the circulation (and hence a direct toxic effect on the brain and other target organs), and secondly, disruption of the liver-thyroid axis (and hence a pattern of specific bipolar symptoms such as is often seen in thyroid disease). Methods: We sought recently-published lay accounts of adverse effects in users of quinoline antimalaria drugs, to test these lay descriptions against our hypothesis on the likely pathogenesis of these effects. Results: We found six lay accounts that described four different experiences of adverse effects arising from the prophylactic use of quinoline antimalaria drugs. All four travellers were healthy, at the start of travel. Two of the travellers experienced severe psychoses, and one had a mild psychosis. The fourth traveller, a serving US soldier, killed 16 unarmed Afghan civilians. Analysis of these accounts shows that, based on our hypothesis, all four travellers had at least one risk factor (most commonly, concurrent alcohol use), for developing a severe reaction to their quinoline antimalaria drug. Our hypothesis therefore predicted a severe adverse drug reaction in each of these four travellers. We also identified a hitherto unrecognized risk factor for developing a severe reaction to quinoline antimalaria drugs—namely, the concurrent use of anabolic steroids. Conclusions: Lay accounts of drug adverse effects can help initiate or further develop medical hypotheses of their pathogenesis. We advise that the quinoline class of antimalaria drugs should be prescribed cautiously, and that mefloquine should not now be prescribed for malaria prophylaxis, under any circumstances whatsoever. Where persistent adverse effects have resulted from the historical use of quinoline antimalaria drugs, we propose a five-point management strategy

关 键 词：AFGHANISTAN Bales Lariam MALARIA MEFLOQUINE Pibloktoq 

分 类 号：R73[医药卫生—肿瘤]